Etzioni R - Search Results

1

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

Telesca D, Etzioni R, Gulati R. Telesca D, et al. Among authors: etzioni r. Biometrics. 2008 Mar;64(1):10-9. doi: 10.1111/j.1541-0420.2007.00825.x. Epub 2007 May 14. Biometrics. 2008. PMID: 17501937

2

Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.

Etzioni R, Berry KM, Legler JM, Shaw P. Etzioni R, et al. Urology. 2002 Feb;59(2):251-5. doi: 10.1016/s0090-4295(01)01516-3. Urology. 2002. PMID: 11834397

3

Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer.

Ramsey SD, Berry K, Etzioni R. Ramsey SD, et al. Among authors: etzioni r. Am J Gastroenterol. 2002 Feb;97(2):440-5. doi: 10.1111/j.1572-0241.2002.05483.x. Am J Gastroenterol. 2002. PMID: 11866285

4

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Etzioni R, et al. J Natl Cancer Inst. 2002 Jul 3;94(13):981-90. doi: 10.1093/jnci/94.13.981. J Natl Cancer Inst. 2002. PMID: 12096083

5

Androgen receptor polymorphisms and the incidence of prostate cancer.

Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M, DiTommaso D, Goodman G. Chen C, et al. Among authors: etzioni r. Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1033-40. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12376504

6

Estimating the influence of rescreening interval on the benefits associated with cancer screening: approaches and limitations.

Weiss NS, Etzioni R. Weiss NS, et al. Among authors: etzioni r. Epidemiology. 2002 Nov;13(6):713-7. doi: 10.1097/00001648-200211000-00017. Epidemiology. 2002. PMID: 12410014 Review.

7

The case for early detection.

Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. Etzioni R, et al. Nat Rev Cancer. 2003 Apr;3(4):243-52. doi: 10.1038/nrc1041. Nat Rev Cancer. 2003. PMID: 12671663 Review.

8

Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.

Lamharzi N, Johnson MM, Goodman G, Etzioni R, Weiss NS, Dightman DA, Barnett M, DiTommaso D, Chen C. Lamharzi N, et al. Among authors: etzioni r. Int J Cancer. 2003 Jul 1;105(4):480-3. doi: 10.1002/ijc.11126. Int J Cancer. 2003. PMID: 12712437

9

Combining biomarkers to detect disease with application to prostate cancer.

Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Etzioni R, et al. Biostatistics. 2003 Oct;4(4):523-38. doi: 10.1093/biostatistics/4.4.523. Biostatistics. 2003. PMID: 14557109

10

Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.

Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE. Chen C, et al. Among authors: etzioni r. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1410-6. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14693730

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results